JP2010535858A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010535858A5 JP2010535858A5 JP2010520992A JP2010520992A JP2010535858A5 JP 2010535858 A5 JP2010535858 A5 JP 2010535858A5 JP 2010520992 A JP2010520992 A JP 2010520992A JP 2010520992 A JP2010520992 A JP 2010520992A JP 2010535858 A5 JP2010535858 A5 JP 2010535858A5
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- compound
- substituted
- benzoxadiazol
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 36
- 239000003814 drug Substances 0.000 claims 14
- 238000004519 manufacturing process Methods 0.000 claims 13
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- -1 substituted Chemical class 0.000 claims 3
- 102000003678 AMPA Receptors Human genes 0.000 claims 2
- 108090000078 AMPA Receptors Proteins 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 230000003444 anaesthetic effect Effects 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 2
- 125000005026 carboxyaryl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 230000002964 excitative effect Effects 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 125000004963 sulfonylalkyl group Chemical group 0.000 claims 2
- 210000000225 synapse Anatomy 0.000 claims 2
- JSXFREXUMJSKSB-UHFFFAOYSA-N 1-(2,1,3-benzoxadiazol-5-yl)octan-1-one Chemical compound C(CCCCCC)C(=O)C1=CC=2C(=NON=2)C=C1 JSXFREXUMJSKSB-UHFFFAOYSA-N 0.000 claims 1
- ICPFDEGHIWLQHT-UHFFFAOYSA-N 2,1,3-benzoxadiazol-5-yl(2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)methanone Chemical compound C1=CC2=NON=C2C=C1C(=O)N1C(CO2)CC2C1 ICPFDEGHIWLQHT-UHFFFAOYSA-N 0.000 claims 1
- VLJBTMQPNFWPHP-UHFFFAOYSA-N 2,1,3-benzoxadiazol-5-yl-(2,3-dichloro-5-azabicyclo[2.2.1]heptan-5-yl)methanone Chemical compound C1=CC2=NON=C2C=C1C(=O)N(C1)C2CC1C(Cl)C2Cl VLJBTMQPNFWPHP-UHFFFAOYSA-N 0.000 claims 1
- QMYRVTKSHZXAMU-UHFFFAOYSA-N 2,1,3-benzoxadiazol-5-yl-(3,3-difluoro-8-azabicyclo[3.2.1]octan-8-yl)methanone Chemical compound C1=CC2=NON=C2C=C1C(=O)N1C2CCC1CC(F)(F)C2 QMYRVTKSHZXAMU-UHFFFAOYSA-N 0.000 claims 1
- OWSSSZMWGUEXGU-UHFFFAOYSA-N 2,1,3-benzoxadiazol-5-yl-(3-fluoro-8-azabicyclo[3.2.1]oct-3-en-8-yl)methanone Chemical compound C1=CC2=NON=C2C=C1C(=O)N1C2CCC1C=C(F)C2 OWSSSZMWGUEXGU-UHFFFAOYSA-N 0.000 claims 1
- GQXWPOIQMPNUNL-UHFFFAOYSA-N 3-azabicyclo[2.2.2]octan-3-yl(2,1,3-benzoxadiazol-5-yl)methanone Chemical compound C1=CC2=NON=C2C=C1C(=O)N1C(CC2)CCC2C1 GQXWPOIQMPNUNL-UHFFFAOYSA-N 0.000 claims 1
- XLCOYPYTNJSQFB-UHFFFAOYSA-N 5-azabicyclo[2.2.1]hept-2-en-5-yl(2,1,3-benzoxadiazol-5-yl)methanone Chemical compound C1=CC2=NON=C2C=C1C(=O)N1C(C=C2)CC2C1 XLCOYPYTNJSQFB-UHFFFAOYSA-N 0.000 claims 1
- FLBFCCXBAQITHK-UHFFFAOYSA-N 8-(2,1,3-benzoxadiazole-5-carbonyl)-8-azabicyclo[3.2.1]octan-3-one Chemical compound C1=CC2=NON=C2C=C1C(=O)N1C2CCC1CC(=O)C2 FLBFCCXBAQITHK-UHFFFAOYSA-N 0.000 claims 1
- JMXIVHHAHKCDSZ-UHFFFAOYSA-N 8-azabicyclo[3.2.1]octan-8-yl(2,1,3-benzoxadiazol-5-yl)methanone Chemical compound C1=CC2=NON=C2C=C1C(=O)N1C2CCC1CCC2 JMXIVHHAHKCDSZ-UHFFFAOYSA-N 0.000 claims 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 208000001914 Fragile X syndrome Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims 1
- 206010038678 Respiratory depression Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- XLCOYPYTNJSQFB-HTLJXXAVSA-N [(4r)-5-azabicyclo[2.2.1]hept-2-en-5-yl]-(2,1,3-benzoxadiazol-5-yl)methanone Chemical compound C1=CC2=NON=C2C=C1C(=O)N1[C@@H](C=C2)CC2C1 XLCOYPYTNJSQFB-HTLJXXAVSA-N 0.000 claims 1
- 229940125717 barbiturate Drugs 0.000 claims 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims 1
- 230000006399 behavior Effects 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 1
- 229940127240 opiate Drugs 0.000 claims 1
- 239000000014 opioid analgesic Substances 0.000 claims 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 claims 1
- 229960004134 propofol Drugs 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 0 C*(**(*)[C@@](C)*1)C1N(*)C(C1=C(C*)*C2=N*N=C2*1)=O Chemical compound C*(**(*)[C@@](C)*1)C1N(*)C(C1=C(C*)*C2=N*N=C2*1)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96436207P | 2007-08-10 | 2007-08-10 | |
| US60/964,362 | 2007-08-10 | ||
| PCT/US2008/009508 WO2009023126A2 (en) | 2007-08-10 | 2008-08-08 | Bicyclic amides for enhancing glutamatergic synaptic responses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010098175A Division JP2010215630A (ja) | 2007-08-10 | 2010-04-21 | グルタミン酸作動性シナプス反応を増大するための二環式アミド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010535858A JP2010535858A (ja) | 2010-11-25 |
| JP2010535858A5 true JP2010535858A5 (enExample) | 2011-08-18 |
| JP5576277B2 JP5576277B2 (ja) | 2014-08-20 |
Family
ID=40351347
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010520992A Expired - Fee Related JP5576277B2 (ja) | 2007-08-10 | 2008-08-08 | グルタミン酸作動性シナプス反応を増大するための二環式アミド |
| JP2010098175A Pending JP2010215630A (ja) | 2007-08-10 | 2010-04-21 | グルタミン酸作動性シナプス反応を増大するための二環式アミド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010098175A Pending JP2010215630A (ja) | 2007-08-10 | 2010-04-21 | グルタミン酸作動性シナプス反応を増大するための二環式アミド |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8263591B2 (enExample) |
| EP (1) | EP2187888B1 (enExample) |
| JP (2) | JP5576277B2 (enExample) |
| KR (2) | KR20100045507A (enExample) |
| CN (2) | CN101862330A (enExample) |
| AU (2) | AU2008287445A1 (enExample) |
| BR (2) | BRPI0823262A2 (enExample) |
| CA (2) | CA2702292A1 (enExample) |
| ES (1) | ES2560095T3 (enExample) |
| MX (2) | MX2010001631A (enExample) |
| NZ (1) | NZ583823A (enExample) |
| RU (2) | RU2010106975A (enExample) |
| SG (1) | SG163526A1 (enExample) |
| WO (1) | WO2009023126A2 (enExample) |
| ZA (1) | ZA201001691B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200904826B (en) | 2007-01-03 | 2010-09-29 | Cortex Pharma Inc | 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses |
| JP5694765B2 (ja) | 2007-05-17 | 2015-04-01 | コーテックス ファーマシューティカルズ， インコーポレイテッド | グルタミン酸作動性シナプス反応を増強するための二置換アミド |
| US8168632B2 (en) | 2007-08-10 | 2012-05-01 | Cortex Pharmaceuticals, Inc. | Bicyclic amide derivatives for the treatment of respiratory disorders |
| ES2560095T3 (es) | 2007-08-10 | 2016-02-17 | Cortex Pharmaceuticals, Inc. | Amidas bicíclicas para mejorar las respuestas sinápticas glutamatérgicas |
| WO2010087980A2 (en) * | 2009-02-02 | 2010-08-05 | Cortex Pharmaceuticals, Inc. | Bicyclic amide derivatives for the treatment of respiratory depression |
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| JP6346862B2 (ja) | 2012-02-07 | 2018-06-20 | エオラス セラピューティクス， インコーポレイテッド | オレキシンレセプターアンタゴニストとしての置換プロリン／ピペリジン |
| TW201613902A (en) | 2014-08-13 | 2016-04-16 | Eolas Therapeutics Inc | Difluoropyrrolidines as orexin receptor modulators |
| US9739787B2 (en) | 2015-09-01 | 2017-08-22 | Abdulmohsen Ebrahim Alterki | Method for diagnosing sleep apnea by measuring adipsin and betatrophin levels |
| US10894789B2 (en) | 2016-02-12 | 2021-01-19 | Astrazeneca Ab | Halo-substituted piperidines as orexin receptor modulators |
| EP3436021B1 (en) * | 2016-03-29 | 2026-07-29 | RespireRx Pharmaceuticals, Inc. | Compositions comprising low impact ampakines for treating attention deficit disorders |
| JP2022534704A (ja) | 2019-06-04 | 2022-08-03 | ヘイガー バイオサイエンシズ，エルエルシー | オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3723436A (en) | 1971-02-25 | 1973-03-27 | Sun Oil Co | Process for aromatic lactams |
| FR2597103B1 (fr) | 1986-04-15 | 1988-12-16 | Provesan Sa | Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde |
| DE69331761T2 (de) | 1992-07-24 | 2002-09-12 | The Regents Of The University Of California, Oakland | Arzneimittel, die den durch ampa rezeptoren vermittelten synaptischen respons erhöhen |
| US20020099050A1 (en) | 1993-07-23 | 2002-07-25 | Lynch Gary S. | Drugs that enhance synaptic responses mediated by AMPA receptors |
| US5650409A (en) | 1995-06-02 | 1997-07-22 | Cortex Pharmaceuticals, Inc. | Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
| US5736543A (en) | 1996-04-03 | 1998-04-07 | The Regents Of The University Of California | Benzoxazines for enhancing synaptic response |
| AU4416197A (en) | 1996-09-17 | 1998-04-14 | Regents Of The University Of California, The | Positive ampa receptor modulation to enhance brain neurotrophic factor expression |
| US6110935A (en) * | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
| US6166008A (en) | 1997-10-27 | 2000-12-26 | Cortex Pharmaceuticals, Inc. | Treatment of schizophrenia with ampakines and neuroleptics |
| US5985871A (en) | 1997-12-24 | 1999-11-16 | Cortex Pharmaceuticals, Inc. | Benzoxazine compounds for enhancing synaptic response |
| RU2214405C2 (ru) | 1998-02-18 | 2003-10-20 | НьюроСёрч А/С | Новые соединения и их применение в качестве положительных модуляторов амра-рецепторов |
| US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| US6303542B1 (en) | 2000-08-18 | 2001-10-16 | Rohm And Haas Company | Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones |
| PA8535601A1 (es) * | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| AUPS255202A0 (en) | 2002-05-27 | 2002-06-13 | Monash University | Agents and methods for the treatment of disorders associated with motor neuron degeneration |
| WO2004089416A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
| US20050085446A1 (en) | 2003-04-14 | 2005-04-21 | Babu M.K. M. | Fluoroquinolone formulations and methods of making and using the same |
| GB0317482D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| BRPI0716375A2 (pt) | 2006-08-31 | 2013-10-15 | Univ Alberta | Método para reduzir ou inibir depressão respiratória em um sujeito; método para induzir analgesia, anestesia ou sedação em um sujeito, reduzindo ou inibindo simultaneamente depressão respiratória no sujeito; e composição farmacêutica para induzir analgesia, anestesia ou sedação em um sujeito... |
| CA2674321A1 (en) | 2007-01-03 | 2008-07-17 | Cortex Pharmaceuticals, Inc. | 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses |
| ZA200904826B (en) | 2007-01-03 | 2010-09-29 | Cortex Pharma Inc | 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses |
| JP5694765B2 (ja) | 2007-05-17 | 2015-04-01 | コーテックス ファーマシューティカルズ， インコーポレイテッド | グルタミン酸作動性シナプス反応を増強するための二置換アミド |
| ES2560095T3 (es) | 2007-08-10 | 2016-02-17 | Cortex Pharmaceuticals, Inc. | Amidas bicíclicas para mejorar las respuestas sinápticas glutamatérgicas |
| NZ584098A (en) | 2007-09-20 | 2012-05-25 | Cortex Pharma Inc | 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses |
-
2008
- 2008-08-08 ES ES08795126.5T patent/ES2560095T3/es active Active
- 2008-08-08 BR BRPI0823262-8A2A patent/BRPI0823262A2/pt not_active Application Discontinuation
- 2008-08-08 MX MX2010001631A patent/MX2010001631A/es active IP Right Grant
- 2008-08-08 MX MX2010001630A patent/MX2010001630A/es unknown
- 2008-08-08 KR KR1020107005366A patent/KR20100045507A/ko not_active Withdrawn
- 2008-08-08 JP JP2010520992A patent/JP5576277B2/ja not_active Expired - Fee Related
- 2008-08-08 SG SG201004604-3A patent/SG163526A1/en unknown
- 2008-08-08 AU AU2008287445A patent/AU2008287445A1/en not_active Abandoned
- 2008-08-08 US US12/733,073 patent/US8263591B2/en not_active Expired - Fee Related
- 2008-08-08 KR KR1020107004015A patent/KR20100051678A/ko not_active Ceased
- 2008-08-08 CN CN201010207140A patent/CN101862330A/zh active Pending
- 2008-08-08 CA CA2702292A patent/CA2702292A1/en not_active Abandoned
- 2008-08-08 WO PCT/US2008/009508 patent/WO2009023126A2/en not_active Ceased
- 2008-08-08 CN CN2008801025333A patent/CN101896183B/zh not_active Expired - Fee Related
- 2008-08-08 RU RU2010106975/04A patent/RU2010106975A/ru not_active Application Discontinuation
- 2008-08-08 CA CA2695742A patent/CA2695742C/en not_active Expired - Fee Related
- 2008-08-08 BR BRPI0814149-5A patent/BRPI0814149A2/pt not_active IP Right Cessation
- 2008-08-08 EP EP08795126.5A patent/EP2187888B1/en active Active
- 2008-08-08 NZ NZ583823A patent/NZ583823A/en not_active IP Right Cessation
-
2010
- 2010-02-17 AU AU2010200563A patent/AU2010200563A1/en not_active Abandoned
- 2010-03-04 RU RU2010107795/15A patent/RU2010107795A/ru not_active Application Discontinuation
- 2010-03-09 ZA ZA2010/01691A patent/ZA201001691B/en unknown
- 2010-04-21 JP JP2010098175A patent/JP2010215630A/ja active Pending
- 2010-09-03 US US12/807,379 patent/US8110584B2/en not_active Expired - Fee Related
-
2012
- 2012-07-25 US US13/557,681 patent/US9492440B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5576277B2 (ja) | グルタミン酸作動性シナプス反応を増大するための二環式アミド | |
| JP2009542613A5 (enExample) | ||
| TNSN07164A1 (en) | Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists | |
| EP2743256A1 (en) | Cyclopropaneamine compound | |
| JP2005510473A5 (enExample) | ||
| JP2010513434A5 (enExample) | ||
| JP2008539267A5 (enExample) | ||
| MX2010012807A (es) | Moduladores del rceptor 5-hidroxitriptamina 3, metodos de fabricacion y uso de los mismos. | |
| TW200304824A (en) | Nicotinamide derivatives useful as PDE4 inhibitors | |
| MX2010012189A (es) | Derivados de quinuclidina como antagonistas del receptor m3 muscarinico. | |
| WO2023019368A1 (en) | 3-cycloamino-indole compounds as serotonergic agents useful for the treatment of disorders related thereto | |
| CA3147105A1 (en) | Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea | |
| ITMI941463A1 (it) | Derivati eterociclo-condensatori di morfinoidi | |
| Nagashima et al. | Novel quinuclidinyl heteroarylcarbamate derivatives as muscarinic receptor antagonists | |
| WO2025104490A9 (en) | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto | |
| TW202342052A (zh) | 用於治療睡眠呼吸中止之ｔａｓｋ１／３通道阻斷劑與正腎上腺素再吸收抑制劑之組合 | |
| JP2025529948A (ja) | セロトニンに関する障害の治療に有用なセロトニン作動薬としてのインドリン誘導体 | |
| TW202342045A (zh) | 用於治療睡眠呼吸中止之ｔａｓｋ１／３通道阻斷劑與ｐ２ｘ３受體拮抗劑之組合 | |
| JP2007530451A (ja) | 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト | |
| TW200406414A (en) | Substituted amino isoxazoline derivatives and their use as anti-depressants | |
| JP2010505919A5 (enExample) | ||
| JP2014524470A (ja) | 神経型ニコチン性アセチルコリン受容体リガンドとしての１，４−ジアザビシクロ［３．２．２］ノナン | |
| JP2012516845A5 (enExample) | ||
| CN118434415A (zh) | 用于治疗睡眠呼吸暂停的task1/3通道阻断剂与毒蕈碱型受体拮抗剂的结合物 | |
| CN102202665A (zh) | 包含毒蕈碱性受体拮抗剂和另一种活性成分的药物产品 |